Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0001394

Fusidic acid for peak identification

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Fusidic acid

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C31H48O6
Número CAS:
6990-06-3
Peso molecular:
516.71
Número MDL:
MFCD00865135
Código UNSPSC:
41116107
ID de substância PubChem:
329831400
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

fusidic acid

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

[H][C@@]12CC[C@@]3(C)[C@@]([H])([C@H](O)C[C@@]4([H])\C([C@H](C[C@]34C)OC(C)=O)=C(/CC\C=C(\C)C)C(O)=O)[C@@]1(C)CC[C@@H](O)[C@H]2C

InChI

1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1

chave InChI

IECPWNUMDGFDKC-MZJAQBGESA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Fusidic acid for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Suppresses nitric oxide lysis of pancreatic islet cells. Inhibits protein synthesis in prokaryotes by inhibiting the ribosome-dependent activity of G factor and translocation of peptidyl-tRNA.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302

Declarações de precaução

P264 - P270 - P301 + P312 - P501

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

David J Farrell et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52 Suppl 7, S487-S492 (2011-05-13)
Fusidic acid binds to elongation factor G (EF-G), preventing its release from the ribosome, thus stalling bacterial protein synthesis. In staphylococci, high-level fusidic acid resistance is usually caused by mutations in the gene encoding EF-G, fusA, and low-level resistance is
D Dobie et al.
Archives of disease in childhood, 89(1), 74-77 (2004-01-08)
This review summarises current knowledge of the microbiological and clinical aspects of fusidic acid resistance in Staphylococcus aureus, and makes recommendations about fusidic acid prescribing and further research.
K Christiansen
International journal of antimicrobial agents, 12 Suppl 2, S73-S78 (1999-10-21)
In 1978 the first report was published indicating that fusidic acid had an immunomodulatory effect. This study describing an in vitro effect on white cells was followed by an in vivo study showing improved survival in heart transplanted mice. In
Mohamed F Mohamed et al.
Drug design, development and therapy, 8, 1979-1983 (2014-11-08)
The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. RR (2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of proinflammatory cytokines
P Collignon et al.
International journal of antimicrobial agents, 12 Suppl 2, S45-S58 (1999-10-21)
Fusidic acid is a narrow spectrum agent that acts to inhibit protein synthesis by inhibition of elongation factor G at the level of the ribosome. Because of high protein binding susceptibility testing in vitro is affected by the presence of
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica